// App-Quantinova.ai

O01 : Do patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?

Researchers

Presenter

  • Gary J Macfarlane

Principal Investigators

  • Ross I R MacDonald

  • Ernest Choy

  • Jon Packham

  • Stefan Siebert

  • Ejaz Pathan

  • Raj Sengupta

  • Lesley Kay

  • Karl Gaffney

  • Gareth T Jones

Medical Centers

  • Epidemiology, University of Aberdeen, Aberdeen, UNITED KINGDOM

  • School of Medicine, Cardiff University, Cardiff, UNITED KINGDOM

  • Institute of Science and Technology in Medicine, Keele University, Keele, UNITED KINGDOM

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Rheumatology, NHS Grampian, Aberdeen, UNITED KINGDOM

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Rheumatology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UNITED KINGDOM

  • Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Fibromyalgia

Biomarkers

  • C reactive protein

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved